186 related articles for article (PubMed ID: 11596036)
1. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma.
Gokgoz N; Wunder JS; Mousses S; Eskandarian S; Bell RS; Andrulis IL
Cancer; 2001 Oct; 92(8):2181-9. PubMed ID: 11596036
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutations in osteosarcomas of low-grade malignancy.
Radig K; Schneider-Stock R; Haeckel C; Neumann W; Roessner A
Hum Pathol; 1998 Nov; 29(11):1310-6. PubMed ID: 9824113
[TBL] [Abstract][Full Text] [Related]
3. Mutation spectrum of p53 gene in highly malignant human osteosarcomas.
Radig K; Schneider-Stock R; Oda Y; Neumann W; Mittler U; Roessner A
Gen Diagn Pathol; 1996 Jun; 142(1):25-32. PubMed ID: 8793483
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A
Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960
[TBL] [Abstract][Full Text] [Related]
5. P53 gene mutations in osteosarcomas in the dog.
van Leeuwen IS; Cornelisse CJ; Misdorp W; Goedegebuure SA; Kirpensteijn J; Rutteman GR
Cancer Lett; 1997 Jan; 111(1-2):173-8. PubMed ID: 9022143
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog.
Johnson AS; Couto CG; Weghorst CM
Carcinogenesis; 1998 Jan; 19(1):213-7. PubMed ID: 9472714
[TBL] [Abstract][Full Text] [Related]
8. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
9. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
Katiyar S; Dash BC; Thakur V; Guptan RC; Sarin SK; Das BC
Cancer; 2000 Apr; 88(7):1565-73. PubMed ID: 10738214
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.
McIntyre JF; Smith-Sorensen B; Friend SH; Kassell J; Borresen AL; Yan YX; Russo C; Sato J; Barbier N; Miser J
J Clin Oncol; 1994 May; 12(5):925-30. PubMed ID: 8164043
[TBL] [Abstract][Full Text] [Related]
11. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.
Toguchida J; Yamaguchi T; Ritchie B; Beauchamp RL; Dayton SH; Herrera GE; Yamamuro T; Kotoura Y; Sasaki MS; Little JB
Cancer Res; 1992 Nov; 52(22):6194-9. PubMed ID: 1423262
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
15. Studies of the RB1 gene and the p53 gene in human osteosarcomas.
Scholz RB; Kabisch H; Weber B; Röser K; Delling G; Winkler K
Pediatr Hematol Oncol; 1992; 9(2):125-37. PubMed ID: 1524989
[TBL] [Abstract][Full Text] [Related]
16. [Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children].
Patiño García A; Sierrasesúmaga Ariznabarreta L
An Esp Pediatr; 1997 Nov; 47(5):478-82. PubMed ID: 9586287
[TBL] [Abstract][Full Text] [Related]
17. P53 gene abnormalities in osteosarcoma.
Guo W; Wang X; Feng C
Chin Med J (Engl); 1996 Oct; 109(10):752-5. PubMed ID: 9275350
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
19. Secondary breast cancer in patients presenting with osteosarcoma: possible involvement of germline p53 mutations.
Russo CL; McIntyre J; Goorin AM; Link MP; Gebhardt MC; Friend SH
Med Pediatr Oncol; 1994; 23(4):354-8. PubMed ID: 8058007
[TBL] [Abstract][Full Text] [Related]
20. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
